A not-so-little role for Lipoprotein(a) in the development of calcific aortic valve disease

Circulation

Volumn 132, Issue 8, 2015, Pages 621-623

  Rogers, Maximillian A ^a   Aikawa, Elena ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Editorials; heart valves; PCSK9 protein human; vascular calcification

Indexed keywords

LIPOPROTEIN A; LYSOPHOSPHATIDIC ACID; PHOSPHODIESTERASE;

AORTA VALVE DISEASE; CALCIFIC AORTIC VALVE DISEASE; CALCIFICATION; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; HEART INFARCTION; HEART VALVE REPLACEMENT; HUMAN; LIPID METABOLISM; MINERAL METABOLISM; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SURFACE PROPERTY; ANIMAL; AORTA VALVE; AORTA VALVE STENOSIS; BIOSYNTHESIS; FEMALE; MALE; METABOLISM;

ANIMALS; AORTIC VALVE; AORTIC VALVE STENOSIS; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; PHOSPHORIC DIESTER HYDROLASES;

EID: 84940657139     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018139     Document Type: Review

References (21)

1. Steinberg D., Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002 8 1211 1217. doi: 10.1038/nm1102-1211
2. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O'Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, Kälsch H, Mühleisen TW, Nöthen MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O'Donnell CJ, Post WS, CHARGE Extracoronary Calcium Working Group Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013 368 503 512. doi: 10.1056/NEJMoa1109034
3. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG., Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014 63 470 477. doi: 10.1016/j.jacc.2013.09.038
4. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G., Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993 13 826 833
5. Freeman RV, Otto CM., Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005 111 3316 3326. doi: 10.1161/CIRCULATIONAHA.104.486738
6. Hutcheson JD, Maldonado N, Aikawa E., Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol 2014 25 327 332. doi: 10.1097/MOL.0000000000000105
7. Bouchareb R, Mahmut A, Nsaibia MJ, Boulanger MC, Dahou A, Lepine JL, Laflamme MH, Hadji F, Couture C, Trahan S, Page S, Bosse Y, Pibarot P, Scipione CA, Romagnuolo R, Koschinsky ML, Arsenault BJ, Marette A, Mathieu P., Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 2015 132 677 690. doi: 10.1161/CIRCULATIONAHA.115.016757
8. Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Després JP, Pibarot P, Bossé Y, Mathieu P., Elevated expression of lipoprotein-Associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 2014 63 460 469. doi: 10.1016/j.jacc.2013.05.105
9. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K., Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002 277 39436 39442. doi: 10.1074/jbc.M205623200
10. Stefan C, Jansen S, Bollen M., NPP-Type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 2005 30 542 550. doi: 10.1016/j.tibs.2005.08.005
11. Gijsbers R, Aoki J, Arai H, Bollen M., The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 2003 538 60 64
12. Moolenaar WH, Perrakis A., Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol 2011 12 674 679. doi: 10.1038/nrm3188. doi: http://dx.doi.org/10.1016/S0014-5793(03)00133-9
13. Yang XP, Amar MJ, Vaisman B, Bocharov AV, Vishnyakova TG, Freeman LA, Kurlander RJ, Patterson AP, Becker LC, Remaley AT., Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013 54 2450 2457. doi: 10.1194/jlr.M038877
14. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014 129 e28 e292. doi: 10.1161/01.cir.0000441139.02102.80
15. Salles JP, Laurencin-Dalicieux S, Conte-Auriol F, Briand-Mésange F, Gennero I., Bone defects in LPA receptor genetically modified mice. Biochim Biophys Acta 2013 1831 93 98. doi: 10.1016/j.bbalip.2012.07.018
16. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031
17. Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MS., AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013 128 962 969. doi: 10.1161/CIRCULATIONAHA.113.001969
18. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S., Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014 129 635 642. doi: 10.1161/CIRCULATIONAHA.113.004406
19. Hutcheson JD, Aikawa E, Merryman WD., Potential drug targets for calcific aortic valve disease. Nat Rev Cardiol 2014 11 218 231. doi: 10.1038/nrcardio.2014.1
20. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL., HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989 80 1313 1319. doi: 10.1161/01.CIR.80.5.1313
21. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015 290 11649 11662